The QUICC study [28] used a centre-controlled design to evaluate the efficacy of a quality improvement programme on 5 health care parameters for ACS patients: ACE-inhibitors at discharge (for patients with heart failure or LV dysfunction, diabetes and hypertension), statins (LDL >3.0 mmol/l, total cholesterol >5.0 mmol/l), clopidogrel (non-ST elevation MI), heparin or LMWH in-hospital (non ST-elevation MI) and coronary angiography (non-ST elevation MI with diabetes, prior MI, ST depression, heart failure). The gene discussed is ACE; the disease is heart failure.